Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Clinical Trial

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL

Author(s): Sven Nilsson, Alexander Stein, Christian Rolfo, Anne L. Kranich, Julia Mann, Konstantinos Papadimitriou, Susann Theile, Stefanie Amberg and Carsten Bokemeyer*

Volume 20 , Issue 10 , 2020

Page: [811 - 817] Pages: 7

DOI: 10.2174/1568009620666200628105727

open access plus

Abstract

Background: Selinexor is an oral Selective Inhibitor of Nuclear Export compound that specifically blocks Chromosomal Region Maintenance protein 1.

Objective: To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients.

Methods: In this multicenter phase I trial, mCRC patients, eligible for oxaliplatin-based treatment, were enrolled to receive oral selinexor on days 1, 3, and 8 plus mFOLFOX6 every two weeks. Primary endpoint was the maximum tolerated dose. Secondary endpoints were toxicity, overall response rate, progression free survival, and overall survival.

Results: Overall, 10 patients were enrolled, who had prior treatment with oxaliplatin (6/10), irinotecan (8/10), bevacizumab (6/10) or anti-EGFR therapy (5/10). Four consecutive patients received 40 mg selinexor plus mFOLFOX6. All four experienced dose-limiting toxicities and withdrew from the study after a median of two cycles. Thus, this dose level was regarded as toxic and no further patients were evaluated at this dose. Six patients were enrolled with 20 mg selinexor plus mFOLFOX6. Despite better tolerability, four patients withdrew (patient wish) after the first cycle and only two patients continued until disease progression. Most commonly reported treatment emergent adverse events were nausea (80%), diarrhea (70%), vomiting (60%), fatigue (60%), anorexia (40%), and impaired vision (40%). Due to the short treatment exposure, no relevant clinical activity was observed.

Conclusion: In patients with metastatic colorectal cancer, selinexor on this dose schedule plus mFOLFOX6 was not tolerable. Other dosing schedules or combinations may be evaluated. Clinical trial identifier NCT02384850.

Keywords: Metastatic colorectal cancer, colorectal cancer, mCRC, selinexor, KPT-330, SINE, FOLFOX, phase I clinical trial.

« Previous
Graphical Abstract
[1]
Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 2011, 61(4), 212-236.
[http://dx.doi.org/10.3322/caac.20121 ] [PMID: 21685461]
[2]
Bokemeyer, C.; Bondarenko, I.; Hartmann, J.T.; de Braud, F.; Schuch, G.; Zubel, A.; Celik, I.; Schlichting, M.; Koralewski, P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol., 2011, 22(7), 1535-1546.
[http://dx.doi.org/10.1093/annonc/mdq632 ] [PMID: 21228335]
[3]
Douillard, J.Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol., 2010, 28(31), 4697-4705.
[http://dx.doi.org/10.1200/JCO.2009.27.4860 ] [PMID: 20921465]
[4]
Grapsa, D.; Syrigos, K.; Saif, M.W. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Rev. Anticancer Ther., 2015, 15(11), 1267-1281.
[http://dx.doi.org/10.1586/14737140.2015.1102063 ] [PMID: 26506906]
[5]
El-Tanani, M.; Dakir, H.; Raynor, B.; Morgan, R. Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers (Basel), 2016, 8(3)E35
[http://dx.doi.org/10.3390/cancers8030035 ] [PMID: 26985906]
[6]
Gravina, G.L.; Senapedis, W.; McCauley, D.; Baloglu, E. Shacham.; Festuccia, C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol., 2014, 7, 85.
[http://dx.doi.org/10.1186/s13045-014-0085-1 ] [PMID: 25476752]
[7]
Turner, J.G.; Dawson, J.; Sullivan, D.M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol., 2012, 83(8), 1021-1032.
[http://dx.doi.org/10.1016/j.bcp.2011.12.016 ] [PMID: 22209898]
[8]
Niu, M.; Chong, Y.; Han, Y.; Liu, X. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. Cancer Biol. Ther., 2015, 16(7), 1110-1118.
[http://dx.doi.org/10.1080/15384047.2015.1047569 ] [PMID: 25996664]
[9]
Abdul Razak, A.R.; Mau-Soerensen, M.; Gabrail, N.Y.; Gerecitano, J.F.; Shields, A.F.; Unger, T.J.; Saint-Martin, J.R.; Carlson, R.; Landesman, Y.; McCauley, D.; Rashal, T.; Lassen, U.; Kim, R.; Stayner, L.A.; Mirza, M.R.; Kauffman, M.; Shacham, S.; Mahipal, A. First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J. Clin. Oncol., 2016, 34(34), 4142-4150.
[http://dx.doi.org/10.1200/JCO.2015.65.3949 ] [PMID: 26926685]
[10]
Turner, J.G.; Dawson, J.; Cubitt, C.L.; Baz, R.; Sullivan, D.M. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin. Cancer Biol., 2014, 27, 62-73.
[http://dx.doi.org/10.1016/j.semcancer.2014.03.001 ] [PMID: 24631834]
[11]
Bahlis, N.J.; Sutherland, H.; White, D.; Sebag, M.; Lentzsch, S.; Kotb, R.; Venner, C.P.; Gasparetto, C.; Del Col, A.; Neri, P.; Reece, D.; Kauffman, M.; Shacham, S.; Unger, T.J.; Jeha, J.; Saint-Martin, J.R.; Shah, J.; Chen, C. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood, 2018, 132(24), 2546-2554.
[http://dx.doi.org/10.1182/blood-2018-06-858852 ] [PMID: 30352784]
[12]
Chari, A.; Vogl, D.T.; Gavriatopoulou, M.; Nooka, A.K.; Yee, A.J.; Huff, C.A.; Moreau, P.; Dingli, D.; Cole, C.; Lonial, S.; Dimopoulos, M.; Stewart, A.K.; Richter, J.; Vij, R.; Tuchman, S.; Raab, M.S.; Weisel, K.C.; Delforge, M.; Cornell, R.F.; Kaminetzky, D.; Hoffman, J.E.; Costa, L.J.; Parker, T.L.; Levy, M.; Schreder, M.; Meuleman, N.; Frenzel, L.; Mohty, M.; Choquet, S.; Schiller, G.; Comenzo, R.L.; Engelhardt, M.; Illmer, T.; Vlummens, P.; Doyen, C.; Facon, T.; Karlin, L.; Perrot, A.; Podar, K.; Kauffman, M.G.; Shacham, S.; Li, L.; Tang, S.; Picklesimer, C.; Saint-Martin, J.R.; Crochiere, M.; Chang, H.; Parekh, S.; Landesman, Y.; Shah, J.; Richardson, P.G.; Jagannath, S. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med., 2019, 381(8), 727-738.
[http://dx.doi.org/10.1056/NEJMoa1903455 ] [PMID: 31433920]
[13]
Kuruvilla, J.; Savona, M.; Baz, R.; Mau-Sorensen, P.M.; Gabrail, N.; Garzon, R.; Stone, R.; Wang, M.; Savoie, L.; Martin, P.; Flinn, I.; Jacoby, M.; Unger, T.J.; Saint-Martin, J.R.; Rashal, T.; Friedlander, S.; Carlson, R.; Kauffman, M.; Shacham, S.; Gutierrez, M. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood, 2017, 129(24), 3175-3183.
[http://dx.doi.org/10.1182/blood-2016-11-750174 ] [PMID: 28468797]
[14]
Gounder, M.M.; Zer, A.; Tap, W.D.; Salah, S.; Dickson, M.A.; Gupta, A.A.; Keohan, M.L.; Loong, H.H.; D’Angelo, S.P.; Baker, S.; Condy, M.; Nyquist-Schultz, K.; Tanner, L.; Erinjeri, J.P.; Jasmine, F.H.; Friedlander, S.; Carlson, R.; Unger, T.J.; Saint-Martin, J.R.; Rashal, T.; Ellis, J.; Kauffman, M.; Shacham, S.; Schwartz, G.K.; Abdul Razak, A.R. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J. Clin. Oncol., 2016, 34(26), 3166-3174.
[http://dx.doi.org/10.1200/JCO.2016.67.6346 ] [PMID: 27458288]
[15]
Services H: Common terminology criteria for adverse events (CTCAE) version 4.03. 2010; National Institutes of Health, National Cancer Institute: USA, 2016.
[16]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026 ] [PMID: 19097774]
[17]
Hesketh, P.J.; Kris, M.G.; Grunberg, S.M.; Beck, T.; Hainsworth, J.D.; Harker, G.; Aapro, M.S.; Gandara, D.; Lindley, C.M. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol., 1997, 15(1), 103-109.
[http://dx.doi.org/10.1200/JCO.1997.15.1.103 ] [PMID: 8996130]
[18]
Cassidy, J.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Rittweger, K.; Gilberg, F.; Saltz, L. XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br. J. Cancer, 2011, 105(1), 58-64.
[http://dx.doi.org/10.1038/bjc.2011.201 ] [PMID: 21673685]
[19]
Díaz-Rubio, E.; Tabernero, J.; Gómez-España, A.; Massutí, B.; Sastre, J.; Chaves, M.; Abad, A.; Carrato, A.; Queralt, B.; Reina, J.J.; Maurel, J.; González-Flores, E.; Aparicio, J.; Rivera, F.; Losa, F.; Aranda, E. Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J. Clin. Oncol., 2007, 25(27), 4224-4230.
[http://dx.doi.org/10.1200/JCO.2006.09.8467 ] [PMID: 17548839]

© 2022 Bentham Science Publishers | Privacy Policy